- AR201 for Egg Allergy Phase 2 Initiation Planned for 2019 -

- Michael Foods Is the Largest U.S. Processor of Value-Added Eggs -

BRISBANE, Calif.-(BUSINESS WIRE)-Dec. 20, 2018- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the submission of its investigational new drug (IND) application for AR201 for the treatment of egg allergy. The company also announced an exclusive supply agreement for egg protein with Michael Foods, Inc., the largest U.S. processor of value-added eggs. Aimmune expects to initiate a Phase 2 clinical trial of AR201 for the treatment of egg allergy in 2019.

Attachments

  • Original document
  • Permalink

Disclaimer

Post Holdings Inc. published this content on 20 December 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 20 December 2018 14:49:14 UTC